SLC5A2 and type 2 diabetes mellitus: Indeed, large randomized controlled trials showed the important and consistent effects of SGLT2-i use in patients with T2DM on reductions in death and major adverse cardiac events (MACE) in people with atherosclerotic cardiovascular disease (ASCVD) or high/very high cardiovascular risk.